CDKN2A and cancer: Given the HPV(+) and HPV(−) oropharyngeal cancers and their molecular changes in p16 and p53 gene expression, we can conclude that patients with HPV(+) cancer with a higher expression of p16 and a lower expression of p53 respond better to treatment and have a better prognosis.